AlereTM. i Influenza A & B. Enter. Molecular results in less than 15 minutes

Transcription

1 Molecular results n less than 15 mnutes Enter

2 Transformng patent management sothermal amplfcaton technology gvng you molecular results, faster than ever before Improvng patent care Gvng you the confdence to make approprate clncal decsons sooner Optmzng operatonal effcency Facltatng effectve patent management Enables prompt ntaton of nfecton control measures Connected results drect to your network Enablng effectve Molecular senstvty n an actonable tmeframe allows the prudent use of antbotcs and antvrals A postve mpact on your faclty Relable near-patent testng reduces overall healthcare costs 1 Confdence at the pont of care and relable, allowng you to respond quckly and accurately n any settng

3 utlzes unque sothermal nuclec acd amplfcaton technology whch does not requre temperature cyclng or a sample purfcaton step Extracton Reverse Transcrpton Amplfcaton Detecton Result Test Test DD/MM/YY R esults Patent: 10axj940 DD/MM/YY User ID: Alereuser1 Patent: 10axj940 User ID: Alereuser1 Flu A: Negatve Flu A: Negatve Flu Flu B: Postve B: Postve New Test New Test 11:22 am Procedural 11:22 am Control Vald Procedural Control Vald Prnt Prnt 0 mn <15 mn

4 s sgnfcantly faster than other molecular methods and more accurate than conventonal rapd testng gvng you the confdence to make effectve patent management decsons sooner Other Rapd Molecular Systems <15 m Other Molecular Systems Conventonal Real-Tme PCR Vral Culture 0m 15m 30m 45m 1h 2h 3h 4h 12h >24h

5 demonstrates mpressve senstvty for the detecton of both nfluenza A and B n clncal respratory specmens obtaned from chldren and adults 2 Alere vs. PCR 3 PPA Influenza A 94.8% (95% CI: 90.1%, 97.4%) 97.7% NPA (95% CI: 95.9%, 98.7%) Influenza B 98.4% 99.4% (95% CI: 94.4%, 99.6%) (95% CI: 98.3%, 99.8%) PPA: Postve Percent Agreement. NPA: Negatve Percent Agreement. Alere vs. Culture 3 Influenza A Influenza B 97.9% b Senstvty (95% CI: 92.6%, 99.4%) (95% CI: 84.6%, 96.5%) 86.2% a 92.5% d 96.5% c Specfcty (95% CI: 82.8%, 89.0%) (95% CI: 94.5%, 97.8%) a. Flu A nuclec acd was detected n 58/66 False Postve specmens usng an FDA-cleared molecular test. b. Flu A nuclec acd was not detected n 1/2 False Negatve specmens usng an FDA-cleared molecular test. c. Flu B nuclec acd was detected n 15/17 False Postve specmens usng an FDA-cleared molecular test. d. Flu B nuclec acd was not detected n 4/6 False Negatve specmens usng an FDA-cleared molecular test.

6 A smple and easy to use molecular dagnostc test 2 Sample type nasal swab and vral transport meda Vsual touchscreen no need for separate nstructons Easy to use requres only mnmal tranng Small footprnt can be used n any healthcare settng Streamlned workflow connectvty can be provded to your network Test Base Sample Recever Transfer Cartrdge 207 mm / mm / mm / 7.64 Smple Easy to Use In Any Settng

7 Easy to use wth a smple touch screen Home 6/Feb/ :00pm Run Test Step 2 of 6 Run Test Run QC Test Revew Memory Insert test base nto devce. Preferences Setup Log Out Run Test Step 4 of 6 Remove seal. Mx swab for 10 seconds and dscard the swab (6:37) Test DD/MM/YY Patent: 10axj940 User ID: Alereuser1 Flu A: Negatve Flu B: Postve New Test 11:22 am Procedural Control Vald Prnt Smple Easy to Use In Any Settng

8 Sutable for use n any healthcare settng Emergency Department Laboratory Physcan's Offce Alere NOW CLIA WAIVED! Smple Easy to Use In Any Settng

9 The Test Target Treat antmcrobal stewardshp ntatve from Alere empowers you to make targeted treatment decsons sooner wth rapd dagnostcs; reducng the napproprate use of antbotcs and antvrals, and the spread of resstance. Fnd out more at TestTargetTreat.com

10 Vst Alere-.com today or contact us: NAT-024 Alere Instrument Alere 24 Test Kt, CPT: Alere Control Swab Kt EQ Alere Barcode Scanner alereprnter Alere Unversal Prnter 1. Bonner, A.B. et al. (2003) Impact of the Rapd Dagnoss of Inuenza on Physcan Decson-Makng and Patent Management n the Pedatrc Emergency Department: of a Randomzed, Prospectve, Controlled Tral. Pedatrcs Vol. 112 No Bell, J. et al. (2013) Clncal Evaluaton of the Alere Inuenza A & B Assay, a Pont-of-Care Rapd Nuclec Acd Amplcaton Test for Detecton of Inuenza. Chldren s Mercy Hosptals and Clncs and Unversty of Mssour Kansas Cty School of Medcne, Kansas Cty, MO. Vertas, P.A., Belton, TX. Natonwde Chldren s Hosptal, Columbus, OH. New York Methodst Hosptal, Brooklyn, NY. Ann & Robert Lure Chldren s Hosptal of Chcago and Northwestern Unversty Fenberg School of Medcne, Chcago, IL. Albany Medcal College, Albany, NY. Wake Forest Unversty Baptst Medcal Center, Wnston-Salem, NC. 3. Alere Package Insert. Call or vst alere.com today 2015 Alere. All rghts reserved. The Alere Logo, Alere, Molecular. In mnutes. and Test Target Treat are trademarks of the Alere group E-04 08/15